490 related articles for article (PubMed ID: 15266099)
1. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
2. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
3. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
[TBL] [Abstract][Full Text] [Related]
4. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
5. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
6. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
8. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
9. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
13. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
15. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Campos SM; Duh MS; Lefebvre P; Rosberg J
J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
[TBL] [Abstract][Full Text] [Related]
16. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
17. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
19. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
[TBL] [Abstract][Full Text] [Related]
20. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
Glaspy J; Degos L; Dicato M; Demetri GD
Oncologist; 2002; 7(2):126-35. PubMed ID: 11961196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]